Biopharma | November 28, 2025
Exyte completes Pharmaplan integration
Pharmaplan brings a pan-European footprint of locations and specialist teams, now operating within Exyte’s Biopharma & Life Sciences division
Pharmaplan brings a pan-European footprint of locations and specialist teams, now operating within Exyte’s Biopharma & Life Sciences division
Clinical trials found that 77% of patients went into remission after receiving obe-cel
The State’s PPP model has already mobilised Rs. 150 crore in core infrastructure, while Thermo Fisher has invested Rs. 90 crore in the Bioprocess Design Centre and its co-located Customer Experience Centre
The new Bioprocess Design Center will serve as a cutting-edge scale-up hub for biologics and vaccine manufacturing
Millions of stroke survivors across the world may soon have a new defense
The facility will offer fully equipped wet labs and strategic scientific support for early-stage biotech companies
Both companies will jointly execute development and scale-up of multiple strategic APIs, including late-stage NCE-1 opportunities
Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii
Subscribe To Our Newsletter & Stay Updated
